Johnson & Johnson (JNJ) Non-cash Items (2010 - 2012)

Johnson & Johnson (JNJ) posted Non-cash Items of $1.0 billion for Q1 2012, up 710570.68% sequentially from $141275.0 in Q1 2011, and up 710570.68% YoY from N/an in Q1 2011.

Johnson & Johnson (JNJ) Non-cash Items (2010 - 2012) Analysis & Trends

Johnson & Johnson (JNJ) has 3 years of Non-cash Items data on file, last reported at $1.0 billion in Q1 2012.

  • Quarterly Non-cash Items rose 710570.68% year-over-year to $1.0 billion in Q1 2012, while the trailing twelve-month figure through Jan 2012 was $1.0 billion (up 710570.68% YoY) and the FY2012 annual result came in at $1.0 billion, up 710570.68% from the prior year.
  • Non-cash Items advanced to $1.0 billion in Q1 2012 per JNJ's latest filing, from $141275.0 in the prior quarter.
  • The five-year high for Non-cash Items was $1.0 billion in Q1 2012, with the low at $141275.0 in Q1 2011.
  • Average Non-cash Items over 3 years is $334.8 million, with a median of $148349.0 recorded in 2010.
  • Year-over-year, Non-cash Items fell 4.77% in 2011 and jumped 710570.68% in 2012.
  • Johnson & Johnson's Non-cash Items stood at $148349.0 in 2010, then decreased by 4.77% to $141275.0 in 2011, then jumped by 710570.68% to $1.0 billion in 2012.
  • Business Quant data shows JNJ's Non-cash Items at $1.0 billion in Q1 2012, $141275.0 in Q1 2011, and $148349.0 in Q1 2010.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn
9 Novartis Ag 113.45 Bn 113.67 Bn -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn

Historic Data

Download Data
DateValue
Jan 1, 2012 1.00 Bn
Jan 1, 2012 1.00 Bn
Jan 2, 2011 648.00 Mn
Jan 2, 2011 648.00 Mn
Jan 3, 2010 1.31 Bn
Jan 3, 2010 1.31 Bn